Posted by Michael Wonder on 03 Feb 2021
Asana BioSciences’ gusacitinib granted FDA fast track designation for moderate to severe chronic hand eczema
4 February 2021 - Asana BioSciences announced today that the U.S. FDA has granted fast track designation to Asana’s gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase and Spleen Tyrosine Kinase, for the treatment of moderate-to-severe chronic hand eczema.
In a recently concluded Phase 2b study in moderate-to-severe chronic hand eczema patients, gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant effects relative to placebo.
